Agenda

3:30 – 4:00 p.m. Registration & Networking
4:00 – 4:15 p.m. Welcome & Introduction
William C. Geary III
Co-Managing Partner
Nutter McClennen & Fish LLP

Jeremy Halpern
Director of Business Development, Emerging Companies Group
Nutter McClennen & Fish LLP

4:15 – 5:00 p.m. Keynote Speaker: Healthcare: Trends in Mergers and Acquisitions
Jonathan Norris
Managing Director
Silicon Valley Bank

Jonathan Norris will present findings from Silicon Valley Bank’s annual report on healthcare venture trends, examining early stage investment, venture fundraising, exit deals, and industry forecasts.

5:00 – 5:45 p.m. Panel: Exits for Life Science Companies

How the Affordable Care Act is changing the definition of value for entrepreneurs, investors and acquirers. The panel will explore the impact of the ACA – with its focus on patient outcomes and cost control – on the building, financing and acquisition of life science companies.

Speakers:

Ambar Bhattacharyya
Vice President
Bessemer Venture Partners

Michael Powell, PhD
General Partner
Sofinnova Ventures

Laurel Sweeney
Senior Director, Health Economics and Reimbursement
Philips Healthcare

Moderated by:

Michelle L. Basil
Chair, Nutter Life Sciences Group

5:45 – 6:00 p.m. Break
6:00 – 6:40 p.m. Interview With CEO

Barbara Fox, Ph.D., Founder & CEO of Avaxia Biologics, will be interviewed by Angel investor and Board Member, Henry Kay, to describe the challenges faced, and solutions identified, in conceptualizing, funding and growing a cutting edge biotechnology company.  Avaxia is a leader in the growing field of orally administered, minimally absorbed therapeutics that are designed to act locally in the gastrointestinal tract.  Having raised capital from government sources, angel groups, micro-VCs and corporate venture capital, Avaxia’s story of outsize value creation and efficient capital is a model for many life science entrepreneurs in today’s challenging regulatory, reimbursement and fundraising environments.

6:40 p.m. Cocktails & Networking